Seigo Baba
Research Subjects
Research Interests
Seigo Baba has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Midori Natsume
Food and Health R&D Laboratories, Meiji Seika Kaisha Ltd., Saitama, 350-0289 Japan
8 shared publicationsNaomi Osakabe
Strategic Information and Ingredient Development Department, Healthcare and Provisions Division, Meiji Seika Kaisha Ltd., Saitama, 104-8002 Japan
8 shared publicationsJunji Terao
Department of Nutrition, School of Medicine, The University of Tokushima, Tokushima 770, Japan
6 shared publicationsAkiko Yasuda
Food and Health R&D Laboratories, Meiji Seika Kaisha Ltd., Saitama, 350-0289 Japan
4 shared publicationsToshio Takizawa
Functional Foods Research and Development Laboratories, Meiji Seika Kaisha, Ltd., 5-3-1 Chiyoda, Sakado-shi, Saitama 350-0289, Japan, and Department of Nutrition, School of Medicine, The University of Tokushima, Kuramoto-cho, Tokushima 770-8503, Japan
4 shared publicationsYuko Muto
From the Food and Health R&D Laboratories, Meiji Seika Kaisha Ltd, Saitama, Japan (SB, NO, MN, AY, KF, and YM); the School of Human Science and Environment, University of Hyogo, Hyogo, Japan (YK); and the Institute of Environmental Science for Human Life, Ochanomizu University, Tokyo, Japan (TK and KK)
3 shared publications
Latest Publications
- Open Access
- 1 June 2007
- Published by Elsevier in The Journal of Nutrition
- Vol. 137 (6) , 1436-1441
Plasma LDL and HDL Cholesterol and Oxidized LDL Concentrations Are Altered in Normo- and Hypercholesterolemic Humans after Intake of Different Levels of Cocoa Powder
Cocoa powder is rich in polyphenols, such as catechins and procyanidins, and has been shown in a variety of subject models to inhibit oxidized LDL and atherogenesis. Our study evaluated plasma LDL cholesterol and oxidized LDL concentrations following the intake of different levels of cocoa powder (13, 19.5, and 26 g/d) in normocholesterolemic and mildly hypercholesterolemic humans. In this comparative, double-blind study, we examined 160 subjects who ingested either cocoa powder containing low-polyphenolic compounds (placebo-cocoa group) or 3 levels of cocoa powder containing high-polyphenolic compounds (13, 19.5, and 26 g/d for low-, middle-, and high-cocoa groups, respectively) for 4 wk. The test powders were consumed as a beverage after the addition of hot water, twice each day. Blood samples were collected at baseline and 4 wk after intake of the test beverages for the measurement of plasma lipids. Plasma oxidized LDL concentrations decreased in the low-, middle-, and high-cocoa groups compared with baseline. A stratified analysis was performed on 131 subjects who had a LDL cholesterol concentrations of ≥3.23 mmol/L at baseline. In these subjects, plasma LDL cholesterol, oxidized LDL, and apo B concentrations decreased, and the plasma HDL cholesterol concentration increased, relative to baseline in the low-, middle-, and high-cocoa groups. The results suggest that polyphenolic substances derived from cocoa powder may contribute to a reduction in LDL cholesterol, an elevation in HDL cholesterol, and the suppression of oxidized LDL.
- 1 June 2007
- Published by Elsevier in The Journal of Nutrition
- Vol. 137 (6) , 1436-1441
Open AccessPlasma LDL and HDL Cholesterol and Oxidized LDL Concentrations Are Altered in Normo- and Hypercholesterolemic Humans after Intake of Different Levels of Cocoa Powder
Cocoa powder is rich in polyphenols, such as catechins and procyanidins, and has been shown in a variety of subject models to inhibit oxidized LDL and atherogenesis. Our study evaluated plasma LDL cholesterol and oxidized LDL concentrations following the intake of different levels of cocoa powder (13, 19.5, and 26 g/d) in normocholesterolemic and mildly hypercholesterolemic humans. In this comparative, double-blind study, we examined 160 subjects who ingested either cocoa powder containing low-polyphenolic compounds (placebo-cocoa group) or 3 levels of cocoa powder containing high-polyphenolic compounds (13, 19.5, and 26 g/d for low-, middle-, and high-cocoa groups, respectively) for 4 wk. The test powders were consumed as a beverage after the addition of hot water, twice each day. Blood samples were collected at baseline and 4 wk after intake of the test beverages for the measurement of plasma lipids. Plasma oxidized LDL concentrations decreased in the low-, middle-, and high-cocoa groups compared with baseline. A stratified analysis was performed on 131 subjects who had a LDL cholesterol concentrations of ≥3.23 mmol/L at baseline. In these subjects, plasma LDL cholesterol, oxidized LDL, and apo B concentrations decreased, and the plasma HDL cholesterol concentration increased, relative to baseline in the low-, middle-, and high-cocoa groups. The results suggest that polyphenolic substances derived from cocoa powder may contribute to a reduction in LDL cholesterol, an elevation in HDL cholesterol, and the suppression of oxidized LDL.
- Open Access
- 1 March 2007
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 85 (3) , 709-717
Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans
Background: Cocoa powder is rich in polyphenols such as catechins and procyanidins and has been shown in various models to inhibit LDL oxidation and atherogenesis. Objective: We examined whether long-term intake of cocoa powder alters plasma lipid profiles in normocholesterolemic and mildly hypercholesterolemic human subjects. Design: Twenty-five subjects were randomly assigned to ingest either 12 g sugar/d (control group) or 26 g cocoa powder and 12 g sugar/d (cocoa group) for 12 wk. Blood samples were collected before the study and 12 wk after intake of the test drinks. Plasma lipids, LDL oxidative susceptibility, and urinary oxidative stress markers were measured. Results: At 12 wk, we measured a 9% prolongation from baseline levels in the lag time of LDL oxidation in the cocoa group. This prolongation in the cocoa group was significantly greater than the reduction measured in the control group (−13%). A significantly greater increase in plasma HDL cholesterol (24%) was observed in the cocoa group than in the control group (5%). A negative correlation was observed between plasma concentrations of HDL cholesterol and oxidized LDL. At 12 wk, there was a 24% reduction in dityrosine from baseline concentrations in the cocoa group. This reduction in the cocoa group was significantly greater than the reduction in the control group (−1%). Conclusion: It is possible that increases in HDL-cholesterol concentrations may contribute to the suppression of LDL oxidation and that polyphenolic substances derived from cocoa powder may contribute to an elevation in HDL cholesterol.
- 1 March 2007
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 85 (3) , 709-717
Open AccessContinuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans
Background: Cocoa powder is rich in polyphenols such as catechins and procyanidins and has been shown in various models to inhibit LDL oxidation and atherogenesis. Objective: We examined whether long-term intake of cocoa powder alters plasma lipid profiles in normocholesterolemic and mildly hypercholesterolemic human subjects. Design: Twenty-five subjects were randomly assigned to ingest either 12 g sugar/d (control group) or 26 g cocoa powder and 12 g sugar/d (cocoa group) for 12 wk. Blood samples were collected before the study and 12 wk after intake of the test drinks. Plasma lipids, LDL oxidative susceptibility, and urinary oxidative stress markers were measured. Results: At 12 wk, we measured a 9% prolongation from baseline levels in the lag time of LDL oxidation in the cocoa group. This prolongation in the cocoa group was significantly greater than the reduction measured in the control group (−13%). A significantly greater increase in plasma HDL cholesterol (24%) was observed in the cocoa group than in the control group (5%). A negative correlation was observed between plasma concentrations of HDL cholesterol and oxidized LDL. At 12 wk, there was a 24% reduction in dityrosine from baseline concentrations in the cocoa group. This reduction in the cocoa group was significantly greater than the reduction in the control group (−1%). Conclusion: It is possible that increases in HDL-cholesterol concentrations may contribute to the suppression of LDL oxidation and that polyphenolic substances derived from cocoa powder may contribute to an elevation in HDL cholesterol.
- 18 February 2004
- Published by Springer Nature in European Journal of Nutrition
- Vol. 44 (1) , 1-9
Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans
Rosmarinic acid (RA) is a natural polyphenolic substance contained in many Lamiaceae herbs such as Perilla frutescens. Previous studies have shown RA has antioxidative and anti-inflammatory activity. However, little is known on the absorption, metabolism, degradation and excretion of RA.
- 18 February 2004
- Published by Springer Nature in European Journal of Nutrition
- Vol. 44 (1) , 1-9
Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans
Rosmarinic acid (RA) is a natural polyphenolic substance contained in many Lamiaceae herbs such as Perilla frutescens. Previous studies have shown RA has antioxidative and anti-inflammatory activity. However, little is known on the absorption, metabolism, degradation and excretion of RA.
- 13 January 2004
- Published by Springer Nature in European Journal of Nutrition
- Vol. 44 (1) , 9
Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans
- 13 January 2004
- Published by Springer Nature in European Journal of Nutrition
- Vol. 44 (1) , 9
Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans
- 1 July 2002
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 33 (1) , 142-148
Absorption and urinary excretion of procyanidin B2 [epicatechin-(4β-8)-epicatechin] in rats
- 1 July 2002
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 33 (1) , 142-148
Absorption and urinary excretion of procyanidin B2 [epicatechin-(4β-8)-epicatechin] in rats
- 17 November 2001
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 49 (12) , 6050-6056
Absorption and Urinary Excretion of (−)-Epicatechin after Administration of Different Levels of Cocoa Powder or (−)-Epicatechin in Rats
(−)-Epicatechin is a major polyphenol component of cocoa powder. The absorption and urinary excretion of (−)-epicatechin following administration of different levels of either cocoa powder (150, 750, and 1500 mg/kg) or (−)-epicatechin (1, 5, and 10 mg/kg) were evaluated in rats. Both the sum of plasma (−)-epicatechin metabolites at 1 h postadministration and peak plasma concentrations increased in a dose-dependent fashion. The sum of (−)-epicatechin metabolites in urine, excreted within 18 h postadministration, also increased with dose. Moreover, the sum of (−)-epicatechin metabolites excreted in urine reached the same level in both (−)-epicatechin and cocoa powder administration groups for equivalent amounts of (−)-epicatechin. These results suggest that, in the dose range examined in this study, bioavailability of (−)-epicatechin following administration of either (−)-epicatechin or cocoa powder shows dose dependence and that the various compounds present in cocoa powder have little effect on the bioavailability of (−)-epicatechin in cocoa powder. Keywords: (−)-Epicatechin; cocoa powder; absorption; excretion; rat
- 17 November 2001
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 49 (12) , 6050-6056
Absorption and Urinary Excretion of (−)-Epicatechin after Administration of Different Levels of Cocoa Powder or (−)-Epicatechin in Rats
(−)-Epicatechin is a major polyphenol component of cocoa powder. The absorption and urinary excretion of (−)-epicatechin following administration of different levels of either cocoa powder (150, 750, and 1500 mg/kg) or (−)-epicatechin (1, 5, and 10 mg/kg) were evaluated in rats. Both the sum of plasma (−)-epicatechin metabolites at 1 h postadministration and peak plasma concentrations increased in a dose-dependent fashion. The sum of (−)-epicatechin metabolites in urine, excreted within 18 h postadministration, also increased with dose. Moreover, the sum of (−)-epicatechin metabolites excreted in urine reached the same level in both (−)-epicatechin and cocoa powder administration groups for equivalent amounts of (−)-epicatechin. These results suggest that, in the dose range examined in this study, bioavailability of (−)-epicatechin following administration of either (−)-epicatechin or cocoa powder shows dose dependence and that the various compounds present in cocoa powder have little effect on the bioavailability of (−)-epicatechin in cocoa powder. Keywords: (−)-Epicatechin; cocoa powder; absorption; excretion; rat
- Open Access
- 1 November 2001
- Published by Elsevier in The Journal of Nutrition
- Vol. 131 (11) , 2885-2891
In Vivo Comparison of the Bioavailability of (+)-Catechin, (−)-Epicatechin and Their Mixture in Orally Administered Rats
We compared levels of (+)-catechin, (−)-epicatechin, and their metabolites in rat plasma and urine after oral administration. Rats were divided into four groups and given (+)-catechin (CA group), (−)-epicatechin (EC group), a mixture of the two (MIX group) or deionized water. Blood samples were collected before administration and at designated time intervals thereafter. Urine samples were collected 0–24 h postadministration. (+)-Catechin, (−)-epicatechin and their metabolites in plasma and urine were analyzed by HPLC-mass spectrometry after treatment with β-glucuronidase and/or sulfatase. After administration, absorbed (+)-catechin and (−)-epicatechin were mainly present in plasma as metabolites, such as nonmethylated or 3′-O-methylated conjugates. In the CA and MIX groups, the primary metabolite of (+)-catechin in plasma was glucuronide in the nonmethylated form. In the EC and MIX groups, in contrast, the primary metabolites of (−)-epicatechin in plasma were glucuronide and sulfoglucuronide in nonmethylated forms, and sulfate in the 3′-O-methylated forms. Urinary excretion of the total amount of (−)-epicatechin metabolites in the EC group was significantly higher than the amount of (+)-catechin metabolites in the CA group. The sum of (+)-catechin metabolites in the urine was significantly lower in the MIX group than in the CA group, and the sum of (−)-epicatechin metabolites in the MIX group was also significantly lower than in the EC group. These results suggest that the bioavailability of (−)-epicatechin is higher than that of (+)-catechin in rats, and that, in combination, (+)-catechin and (−)-epicatechin might be absorbed competitively in the gastrointestinal tract of rats.
- 1 November 2001
- Published by Elsevier in The Journal of Nutrition
- Vol. 131 (11) , 2885-2891
Open AccessIn Vivo Comparison of the Bioavailability of (+)-Catechin, (−)-Epicatechin and Their Mixture in Orally Administered Rats
We compared levels of (+)-catechin, (−)-epicatechin, and their metabolites in rat plasma and urine after oral administration. Rats were divided into four groups and given (+)-catechin (CA group), (−)-epicatechin (EC group), a mixture of the two (MIX group) or deionized water. Blood samples were collected before administration and at designated time intervals thereafter. Urine samples were collected 0–24 h postadministration. (+)-Catechin, (−)-epicatechin and their metabolites in plasma and urine were analyzed by HPLC-mass spectrometry after treatment with β-glucuronidase and/or sulfatase. After administration, absorbed (+)-catechin and (−)-epicatechin were mainly present in plasma as metabolites, such as nonmethylated or 3′-O-methylated conjugates. In the CA and MIX groups, the primary metabolite of (+)-catechin in plasma was glucuronide in the nonmethylated form. In the EC and MIX groups, in contrast, the primary metabolites of (−)-epicatechin in plasma were glucuronide and sulfoglucuronide in nonmethylated forms, and sulfate in the 3′-O-methylated forms. Urinary excretion of the total amount of (−)-epicatechin metabolites in the EC group was significantly higher than the amount of (+)-catechin metabolites in the CA group. The sum of (+)-catechin metabolites in the urine was significantly lower in the MIX group than in the CA group, and the sum of (−)-epicatechin metabolites in the MIX group was also significantly lower than in the EC group. These results suggest that the bioavailability of (−)-epicatechin is higher than that of (+)-catechin in rats, and that, in combination, (+)-catechin and (−)-epicatechin might be absorbed competitively in the gastrointestinal tract of rats.
- Open Access
- 1 November 2000
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 84 (5) , 673-680
Cocoa powder enhances the level of antioxidative activity in rat plasma
The aims of the present study were to determine the level of (-)-epicatechin (EC) and its metabolites in rat plasma after oral administration of cocoa powder and to evaluate the protective effect of cocoa powder in terms of suppressing the oxidation of plasma components. Rats were orally administered 1 g cocoa powder/kg body weight, containing 7·80 mg EC, and their blood was collected before administration and at designated time intervals thereafter. The EC and its metabolites in plasma were treated with β-glucuronidase and/or sulfatase, then analysed by HPLC and by liquid chromatography–MS. Several EC-related compounds were detected in plasma such as free EC, and glucuronide, sulfate, and glucuronide–sulfate conjugates of non-methylated or methylated EC. All EC metabolites showed a maximum concentration in plasma at 30–60 min post-administration. Glucuronide conjugates of both non-methylated and methylated EC were found in high concentration in plasma. Moreover, administration of cocoa powder significantly reduced the accumulation of lipid peroxides in plasma and significantly reduced the consumption of α-tocopherol in plasma oxidized by treatment with 2,2′-azobis-(2-amidinopropane) dihydrochloride (AAPH (25 mmol/l)) or CuSO4 (100 μmol/l) compared with that in the case of plasma obtained before administration. The total EC concentration in plasma was negatively correlated with the level of accumulation of lipid peroxides in plasma oxidized by treatment with AAPH (25 mmol/l) and was positively correlated with the level of residual α-tocopherol in plasma oxidized by treatment with CuSO4 (100 μmol/l). These results indicate that EC in cocoa powder was absorbed from the digestive tract, that various conjugated forms of EC were generated in the digestive tract and distributed to the plasma, and that these enhanced the antioxidative activity of plasma.
- 1 November 2000
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 84 (5) , 673-680
Open AccessCocoa powder enhances the level of antioxidative activity in rat plasma
The aims of the present study were to determine the level of (-)-epicatechin (EC) and its metabolites in rat plasma after oral administration of cocoa powder and to evaluate the protective effect of cocoa powder in terms of suppressing the oxidation of plasma components. Rats were orally administered 1 g cocoa powder/kg body weight, containing 7·80 mg EC, and their blood was collected before administration and at designated time intervals thereafter. The EC and its metabolites in plasma were treated with β-glucuronidase and/or sulfatase, then analysed by HPLC and by liquid chromatography–MS. Several EC-related compounds were detected in plasma such as free EC, and glucuronide, sulfate, and glucuronide–sulfate conjugates of non-methylated or methylated EC. All EC metabolites showed a maximum concentration in plasma at 30–60 min post-administration. Glucuronide conjugates of both non-methylated and methylated EC were found in high concentration in plasma. Moreover, administration of cocoa powder significantly reduced the accumulation of lipid peroxides in plasma and significantly reduced the consumption of α-tocopherol in plasma oxidized by treatment with 2,2′-azobis-(2-amidinopropane) dihydrochloride (AAPH (25 mmol/l)) or CuSO4 (100 μmol/l) compared with that in the case of plasma obtained before administration. The total EC concentration in plasma was negatively correlated with the level of accumulation of lipid peroxides in plasma oxidized by treatment with AAPH (25 mmol/l) and was positively correlated with the level of residual α-tocopherol in plasma oxidized by treatment with CuSO4 (100 μmol/l). These results indicate that EC in cocoa powder was absorbed from the digestive tract, that various conjugated forms of EC were generated in the digestive tract and distributed to the plasma, and that these enhanced the antioxidative activity of plasma.
- 1 January 2000
- Published by Taylor & Francis in Free Radical Research
- Vol. 33 (5) , 635-641
Bioavailability of (-)-epicatechin upon intake of chocolate and cocoa in human volunteers
We evaluated the levels of (-)-epicatechin (EC) and its metabolites in plasma and urine after intake of chocolate or cocoa by male volunteers. EC metabolites were analyzed by HPLC and LC/MS after glucuronidase and/or sulfatase treatment. The maximum levels of total EC metabolites in plasma were reached 2 hours after either chocolate or cocoa intake. Sulfate, glucuronide, and sulfoglucuronide (mixture of sulfate and glucuronide) conjugates of nonmethylated EC were the main metabolites present in plasma rather than methylated forms. Urinary excretion of total EC metabolites within 24 hours after chocolate or cocoa intake was 29.8 ± 5.3% and 25.3 ± 8.1% of total EC intake. EC in chocolate and cocoa was partly absorbed and was found to be present as a component of various conjugates in plasma, and these were rapidly excreted in urine.
- 1 January 2000
- Published by Taylor & Francis in Free Radical Research
- Vol. 33 (5) , 635-641
Bioavailability of (-)-epicatechin upon intake of chocolate and cocoa in human volunteers
We evaluated the levels of (-)-epicatechin (EC) and its metabolites in plasma and urine after intake of chocolate or cocoa by male volunteers. EC metabolites were analyzed by HPLC and LC/MS after glucuronidase and/or sulfatase treatment. The maximum levels of total EC metabolites in plasma were reached 2 hours after either chocolate or cocoa intake. Sulfate, glucuronide, and sulfoglucuronide (mixture of sulfate and glucuronide) conjugates of nonmethylated EC were the main metabolites present in plasma rather than methylated forms. Urinary excretion of total EC metabolites within 24 hours after chocolate or cocoa intake was 29.8 ± 5.3% and 25.3 ± 8.1% of total EC intake. EC in chocolate and cocoa was partly absorbed and was found to be present as a component of various conjugates in plasma, and these were rapidly excreted in urine.